1887

Abstract

The development of live-attenuated vaccines against Dengue virus (DENV) has been problematic. Dengvaxia, licensed in several countries where DENV is endemic, has shown low efficacy profiles and there are safety concerns prohibiting its administration to children younger than 9 years old, and the live-attenuated tetravalent vaccine (LATV) developed by NIAID has proven too reactogenic during clinical trialing. In this work we examined whether the combination of TV005, a LATV-derived formulation, with Tetra DIIIC, a subunit vaccine candidate based on fusion proteins derived from structural proteins from all four DENV serotypes, can overcome the respective limitations of these two vaccine approaches. Rhesus macaques were first primed with one or two doses of Tetra DIIIC and then boosted with TV005, following the time course of the appearance of virus-binding and neutralizing antibodies, and evaluating protection by means of a challenge experiment with wild-type viruses. Although the two evaluated prime-boost regimes were equivalent to a single administration of TV005 in terms of the development of virus-binding and neutralizing antibodies as well as the protection against viral challenge, both regimes reduced vaccine viremia to undetectable levels. Thus, the combination of Tetra DIIIC with TV005 offers a potential solution to the reactogenicity problems, which have beset the development of the latter vaccine candidate.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.001271
2019-05-15
2019-10-18
Loading full text...

Full text loading...

References

  1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW et al. The global distribution and burden of dengue. Nature 2013;496:504–507 [CrossRef]
    [Google Scholar]
  2. Gubler DJ. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol 2002;10:100–103 [CrossRef]
    [Google Scholar]
  3. Halstead SB. Dengue London: Imperial College Press; 2008
  4. Halstead SB. Dengue. Lancet 2007;370:1644–1652 [CrossRef]
    [Google Scholar]
  5. Katzelnick LC, Harris E, Baric R, Coller B-A, Coloma J. Immune correlates of protection for dengue: state of the art and research agenda. Vaccine 2017;35:4659–4669 [CrossRef]
    [Google Scholar]
  6. Fahimi H, Mohammadipour M, Haddad Kashani H, Parvini F, Sadeghizadeh M. Dengue viruses and promising envelope protein domain III-based vaccines. Appl Microbiol Biotechnol 2018;102:2977–2996 [CrossRef]
    [Google Scholar]
  7. Russell PK, Halstead SB. Challenges to the design of clinical trials for live-attenuated tetravalent dengue vaccines. PLoS Negl Trop Dis 2016;10:e0004854 [CrossRef]
    [Google Scholar]
  8. Feinberg MB, Ahmed R. Advancing dengue vaccine development. Science 2017;358:865–866 [CrossRef]
    [Google Scholar]
  9. Durbin AP, Kirkpatrick BD, Pierce KK, Carmolli MP, Tibery CM et al. A 12-Month-Interval dosing study in adults indicates that a single dose of the National Institute of allergy and infectious diseases tetravalent dengue vaccine induces a robust neutralizing antibody response. J Infect Dis 2016;214:832–835 [CrossRef]
    [Google Scholar]
  10. Osorio JE, Wallace D, Stinchcomb DT. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone. Expert Rev Vaccines 2016;15:497–508 [CrossRef]
    [Google Scholar]
  11. Kirkpatrick BD, Durbin AP, Pierce KK, Carmolli MP, Tibery CM et al. Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, Flavivirus-Naive adults. J Infect Dis 2015;212:702–710 [CrossRef]
    [Google Scholar]
  12. Rupp R, Luckasen GJ, Kirstein JL, Osorio JE, Santangelo JD et al. Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: a phase 1B randomized study. Vaccine 2015;33:6351–6359 [CrossRef]
    [Google Scholar]
  13. Osorio JE, Velez ID, Thomson C, Lopez L, Jimenez A et al. Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. Lancet Infect Dis 2014;14:830–838 [CrossRef]
    [Google Scholar]
  14. Osorio JE, Partidos CD, Wallace D, Stinchcomb DT. Development of a recombinant, chimeric tetravalent dengue vaccine candidate. Vaccine 2015;33:7112–7120 [CrossRef]
    [Google Scholar]
  15. Osorio JE, Huang CY-H, Kinney RM, Stinchcomb DT. Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. Vaccine 2011;29:7251–7260 [CrossRef]
    [Google Scholar]
  16. Yauch LE, Zellweger RM, Kotturi MF, Qutubuddin A, Sidney J et al. A protective role for dengue virus-specific CD8+ T cells. J Immunol 2009;182:4865–4873 [CrossRef]
    [Google Scholar]
  17. Zellweger RM, Miller R, Eddy WE, White LJ, Johnston RE et al. Role of humoral versus cellular responses induced by a protective dengue vaccine candidate. PLoS Pathog 2013;9:e1003723 [CrossRef]
    [Google Scholar]
  18. Weiskopf D, Angelo MA, de Azeredo EL, Sidney J, Greenbaum JA et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc Natl Acad Sci U S A 2013;110:E2046–E2053 [CrossRef]
    [Google Scholar]
  19. Weiskopf D, Sette A. T-cell immunity to infection with dengue virus in humans. Front Immunol 2014;5:93 [CrossRef]
    [Google Scholar]
  20. McArthur MA, A Promising ER. Single-dose, live attenuated tetravalent dengue vaccine candidate. J Infect Dis 2015
    [Google Scholar]
  21. Kardani K, Bolhassani A, Shahbazi S. Prime-boost vaccine strategy against viral infections: mechanisms and benefits. Vaccine 2016;34:413–423 [CrossRef]
    [Google Scholar]
  22. Suzarte E, Marcos E, Gil L, Valdés I, Lazo L et al. Generation and characterization of potential dengue vaccine candidates based on domain III of the envelope protein and the capsid protein of the four serotypes of dengue virus. Arch Virol 2014;159:1629–1640 [CrossRef]
    [Google Scholar]
  23. Suzarte E, Gil L, Valdés I, Marcos E, Lazo L et al. A novel tetravalent formulation combining the four aggregated domain III-capsid proteins from dengue viruses induces a functional immune response in mice and monkeys. Int Immunol 2015;27:367–379 [CrossRef]
    [Google Scholar]
  24. Gil L, Lazo L, Valdés I, Suzarte E, Yen P et al. The tetravalent formulation of domain III-capsid proteins recalls memory B- and T-cell responses induced in monkeys by an experimental dengue virus infection. Clin Transl Immunology 2017;6:e148 [CrossRef]
    [Google Scholar]
  25. Lazo Vázquez L, Suzarte Portal E, Castro Velazco J, Yen P, Dung LT et al. Screening for immune response against dengue virus in Vietnamese non-human primates: implications for vaccine developers. Clin Transl Immunology 2017;6:e135 [CrossRef]
    [Google Scholar]
  26. Blaney JE, Matro JM, Murphy BR, Whitehead SS. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. J Virol 2005;79:5516–5528 [CrossRef]
    [Google Scholar]
  27. Kilgore KM, Murphy MK, Burton SL, Wetzel KS, Smith SA et al. Characterization and implementation of a diverse simian immunodeficiency virus SIVsm envelope panel in the assessment of neutralizing antibody breadth elicited in rhesus macaques by multimodal vaccines expressing the SIVmac239 envelope. J Virol 2015;89:8130–8151 [CrossRef]
    [Google Scholar]
  28. Hu X, Valentin A, Dayton F, Kulkarni V, Alicea C et al. DNA prime-boost vaccine regimen to increase breadth, Magnitude, and cytotoxicity of the cellular immune responses to subdominant Gag epitopes of simian immunodeficiency virus and HIV. J Immunol 2016;197:3999–4013 [CrossRef]
    [Google Scholar]
  29. Andersson A-MC, Holst PJ. Increased T cell breadth and antibody response elicited in prime-boost regimen by viral vector encoded homologous SIV Gag/Env in outbred cd1 mice. J Transl Med 2016;14:343 [CrossRef]
    [Google Scholar]
  30. Gil L, Marcos E, Izquierdo A, Lazo L, Valdés I et al. The protein DIIIC-2, aggregated with a specific oligodeoxynucleotide and adjuvanted in alum, protects mice and monkeys against DENV-2. Immunol Cell Biol 2015;93:57–66 [CrossRef]
    [Google Scholar]
  31. Valdés I, Bernardo L, Gil L, Pavón A, Lazo L et al. A novel fusion protein domain III-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice. Virology 2009;394:249–258 [CrossRef]
    [Google Scholar]
  32. Weiskopf D, Angelo MA, Grifoni A, O'Rourke PH, Sidney J et al. HLA-DRB1 alleles are associated with different magnitudes of dengue virus-specific CD4+ T-cell responses. J Infect Dis 2016;214:1117–1124 [CrossRef]
    [Google Scholar]
  33. Gil L, Cobas K, Lazo L, Marcos E, Hernández L et al. A tetravalent formulation based on recombinant nucleocapsid-like particles from dengue viruses induces a functional immune response in mice and monkeys. J Immunol 2016;In Press:
    [Google Scholar]
  34. Weiskopf D, Angelo MA, Bangs DJ, Sidney J, Paul S et al. The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes. J Virol 2015;89:120–128 [CrossRef]
    [Google Scholar]
  35. Grifoni A, Angelo MA, Lopez B, O'Rourke PH, Sidney J et al. Global assessment of dengue virus-specific CD4+ T cell responses in dengue-endemic areas. Front Immunol 2017;8:1309 [CrossRef]
    [Google Scholar]
  36. Whitehead SS. Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine?. Expert Rev Vaccines 2016;15:509–517 [CrossRef]
    [Google Scholar]
  37. Durbin AP, Kirkpatrick BD, Pierce KK, Elwood D, Larsson CJ et al. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial. J Infect Dis 2013;207:957–965 [CrossRef]
    [Google Scholar]
  38. Kaufman BM, Summers PL, Dubois DR, Eckels KH. Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection. Am J Trop Med Hyg 1987;36:427–434 [CrossRef]
    [Google Scholar]
  39. Valdés I, Hermida L, Martín J, Menéndez T, Gil L et al. Immunological evaluation in nonhuman primates of formulations based on the chimeric protein P64k-domain III of dengue 2 and two components of Neisseria meningitidis. Vaccine 2009;27:995–1001 [CrossRef]
    [Google Scholar]
  40. Durbin AP, Karron RA, Sun W, Vaughn DW, Reynolds MJ, Chanock RM, Whitehead SS, Murphy BR et al. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. Am J Trop Med Hyg 2001;65:405–413 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.001271
Loading
/content/journal/jgv/10.1099/jgv.0.001271
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Supplementary material 1

EXCEL

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error